...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Plasmidfactory obtained worldwide license from DKFZ for manufacture of pDG helper/packaging vectors

| Print |
Thursday, 08 February 2007 00:00 (UTC + 1)

 

PlasmidFactory (Bielefeld, Germany), a leading contract manufacturer for plasmid DNA, has obtained a worldwide license from the German Cancer Research Center DKFZ (Heidelberg, Germany) for the manufacture and the marketing of the pDG helper/packaging vector series used for adeno-associated virus (AAV) production.

 

The license agreement extends to multiple vector serotypes such as pDG, pDM, and pDP1rs to pDP6rs as well as the pDG without heparin binding motive and other helper/packaging vectors. PlasmidFactory, who manufactures these vectors in stock for immediate shipment, is furthermore allowed to issue sub-licenses to other distributors to assure efficient and worldwide sales and distribution.

 

Cotransfection of cells with pDG and AAV vector plasmid is sufficient for production of infectious recombinant AAV, since the pDG vectors contain all AAV and adenovirus functions required for amplification and packaging of AAV vector plasmids. For optimal co-transfection results homogenous supercoiled ccc-plasmid DNA is a prerequisite, which is manufactured up to GMP Grade Quality by PlasmidFactory and characterized using the capillary gel electrophoresis (CGE) technology.

 

Over the past decade, AAV-based vectors have emerged as promising candidates for gene therapeutic applications. AAV is a naturally occurring virus that is not associated with any disease in humans and that is therefore used to ferry helpful genes into target cells.


Standard protocols necessitate overinfection with helper virus resulting in virus contaminated recombinant AAV stocks. The pDG vectors, which have been developed by Dr. Dirk Grimm in the team of Dr. Jürgen Kleinschmidt (DKFZ), make helper virus overinfection dispensable thus making them a promising tool for gene therapy applications.

 

 

About PlasmidFactory - www.plasmidfactory.com

PlasmidFactory is a contract manufacturer for plasmid DNA from research scale (e.g. 10 mg) up to industrial scale for R&D, veterinary or human DNA vaccination, gene therapy, virus production, drug delivery, or tumor therapy. The plasmid DNA is manufactured from Research Grade up to GMP-Grade quality without using any animal-derived components.

Besides the service production of plasmid DNA, the company offers on-stock plasmids for reporter gene vectors, mock transfections, and pDG vectors for AAV virus production.
The company has developed the capillary gel electrophoresis (CGE). CGE is a useful tool for plasmid quality control and storage, stability assessment.


 

For further information about the company:

Dr. Martin Schleef
PlasmidFactory GmbH & Co. KG
Phone: 0049 (0) 521 - 299 735 - 0
This e-mail address is being protected from spambots. You need JavaScript enabled to view it